Industry Focus
Healthcare: Why This $6 Billion Biotech Stock Is Skyrocketing 70% in November
- Autor: Vários
- Narrador: Vários
- Editora: Podcast
- Duração: 0:22:35
- Mais informações
Informações:
Sinopse
A flurry of news has investors clamoring to add Nektar Therapeutics to their portfolios. Plus, we explain why investors are disappointed by Loxo Oncology’s good news and how a new smart pill could change medicine forever.
